Key result
This review highlights newly-approved drugs for PAH, including macitentan, riociguat, and selexipag, as well as initial up-front combination therapy and potential future signaling pathways.
This review summarizes newly approved drugs (macitentan, riociguat, selexipag) and novel therapeutic approaches like up-front combination therapy for pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Expands PAH therapeutic options with new agents and up-front combinations; leaves open optimal sequencing and long-term outcomes.
Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
No takes yet. Share an insight, caveat, or question.
Mercurio et al. (2018) conducted a review in Pulmonary Arterial Hypertension (PAH). Newly-approved drugs (macitentan, riociguat, selexipag) and combination therapy was evaluated. This review highlights newly-approved drugs for PAH, including macitentan, riociguat, and selexipag, as well as initial up-front combination therapy and potential future signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: